Today: 24 April 2026
Subscribe
Browse Category

SGX:SET 10 December 2025

Stock Market Today

  • Hims Stock Surges on Key FDA Review of Peptides Offering New Growth Path
    April 23, 2026, 6:11 PM EDT. Hims & Hers (HIMS) shares have climbed more than 50% in two weeks following the U.S. Food and Drug Administration's announcement of a July meeting to review peptide compounds for expanded access. The FDA panel will evaluate several peptides, including BPC-157 and Semax, marking a potential gateway for Hims' peptide-focused strategies. This development injects a fresh growth narrative amid Hims' pivot from compounded GLP-1 weight-loss drugs to FDA-approved treatments, aligning with Novo Nordisk's products. Earlier, Hims acquired a California peptide manufacturing facility to bolster supply and innovation in areas like metabolic health and cognitive performance. Strong underlying fundamentals back the rally, with Q4 revenue up 28% year-on-year to $617.8 million and full-year revenue at $2.35 billion, a 59% increase. Investors see peptides as a durable growth driver beyond previous headlines.

Latest article

Comfort Systems USA Stock Jumps After Profit More Than Doubles On Data Center Demand

Comfort Systems USA Stock Jumps After Profit More Than Doubles On Data Center Demand

24 April 2026
Comfort Systems USA reported first-quarter net income of $370.4 million, more than double last year’s $169.3 million, as revenue surged 56.5% to $2.87 billion on strong demand from technology-sector projects, especially data centers. Backlog climbed to $12.45 billion. Shares rose $52.18 to $1,773.91 in late trading. The board raised the quarterly dividend to 80 cents a share.
American Express Earnings Beat Shows Wealthy Cardholders Still Spending — But AXP Stock Drops

American Express Earnings Beat Shows Wealthy Cardholders Still Spending — But AXP Stock Drops

24 April 2026
American Express posted first-quarter earnings per share of $4.28, beating LSEG estimates, as billed business hit $428 billion and FX-adjusted spending rose 9%. Net income climbed 15% to $2.97 billion, with revenue up 11% to $18.91 billion. The company kept its 2026 revenue and profit outlook unchanged. Shares fell despite the profit beat, as investors noted flat guidance and signs of weaker travel spending.
AMD Stock Brushes $320 After Stifel Call, With May 5 Earnings Now the Real Test

AMD Stock Brushes $320 After Stifel Call, With May 5 Earnings Now the Real Test

23 April 2026
AMD shares touched $319.71 Thursday before retreating to $305.33, valuing the company at about $501 billion. The move comes ahead of first-quarter results on May 5, as investors watch for revenue from major AI chip deals with Meta and OpenAI. Stifel raised its price target to $320, citing strong AI demand and new products. AMD reported record Q4 revenue in February, with data-center sales up 39%.
Go toTop